March 22 (Reuters) – Novavax Inc talked about on Tuesday its COVID-19 vaccine has obtained emergency-utilize authorization from the Remedy Controller Total of India for youngsters weak 12 to 17 years.
The authorization is a global first for the age neighborhood for the vaccine, which is manufactured and marketed in India by the Serum Institute of India below the logo title Covovax.
Novavax closing month talked about its vaccine used to be 80% effective against COVID-19 in a gradual-stage trial attempting out the shot in 2,247 youngsters weak 12 to 17 years.
The firm talked about on Tuesday its vaccine produced an immune response within the the same age neighborhood in a mid- to gradual-stage gape appealing 460 Indian formative years.
Covovax is the fourth COVID-19 vaccine to be well-liked for formative years weak 12 years and older in India after Organic E’s Corbevax, Zydus Cadila’s ZyCoV-D and Bharat Biotech’s Covaxin.
India, which had up to now been vaccinating youngsters weak 15 and above, started administering doses of Organic E’s Corbevax closing week to youngsters weak 12 to 14.
The nation’s drug regulator in December well-liked Novavax’s COVID-19 vaccine for folks weak 18 years and above. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)